BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29556023)

  • 1. Demethylator phenotypes in acute myeloid leukemia.
    Kelly AD; Madzo J; Madireddi P; Kropf P; Good CR; Jelinek J; Issa JJ
    Leukemia; 2018 Oct; 32(10):2178-2188. PubMed ID: 29556023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
    Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
    Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of NPM1 Gene Mutations in AML.
    Hindley A; Catherwood MA; McMullin MF; Mills KI
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
    Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
    Mechaal A; Menif S; Abbes S; Safra I
    Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
    Mosquera Orgueira A; Peleteiro Raíndo A; Cid López M; Antelo Rodríguez B; Díaz Arias JÁ; Ferreiro Ferro R; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; Melero Valentín P; González Pérez MS; Cerchione C; Martinelli G; Montesinos Fernández P; Pérez Encinas MM; Bello López JL
    PLoS One; 2021; 16(2):e0247093. PubMed ID: 33592069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.
    Tsai CH; Hou HA; Tang JL; Liu CY; Lin CC; Chou WC; Tseng MH; Chiang YC; Kuo YY; Liu MC; Liu CW; Lin LI; Tsay W; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tien HF
    Leukemia; 2016 Jul; 30(7):1485-92. PubMed ID: 27055875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
    Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
    J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
    Elrhman HAEA; El-Meligui YM; Elalawi SM
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
    Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
    Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.